JP2023504445A5 - - Google Patents
Info
- Publication number
- JP2023504445A5 JP2023504445A5 JP2022532037A JP2022532037A JP2023504445A5 JP 2023504445 A5 JP2023504445 A5 JP 2023504445A5 JP 2022532037 A JP2022532037 A JP 2022532037A JP 2022532037 A JP2022532037 A JP 2022532037A JP 2023504445 A5 JP2023504445 A5 JP 2023504445A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- nhr
- compound according
- aryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PLPCT/PL2019/000109 | 2019-11-27 | ||
| PL2019000109 | 2019-11-27 | ||
| PCT/EP2020/083596 WO2021105334A1 (en) | 2019-11-27 | 2020-11-27 | Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023504445A JP2023504445A (ja) | 2023-02-03 |
| JP2023504445A5 true JP2023504445A5 (enExample) | 2023-12-05 |
| JP7852923B2 JP7852923B2 (ja) | 2026-04-28 |
Family
ID=69024572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022532037A Active JP7852923B2 (ja) | 2019-11-27 | 2020-11-27 | セレブロンに結合するピペリジン－２，６－ジオン誘導体、及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240343706A1 (enExample) |
| EP (1) | EP4065571A1 (enExample) |
| JP (1) | JP7852923B2 (enExample) |
| KR (1) | KR20220106801A (enExample) |
| CN (1) | CN115023419A (enExample) |
| AU (1) | AU2020392427B2 (enExample) |
| WO (1) | WO2021105334A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022255888A1 (en) * | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
| WO2024015340A1 (en) * | 2022-07-12 | 2024-01-18 | Regents Of The University Of Michigan | Cereblon ligands and uses thereof |
| JP2025531869A (ja) | 2022-09-09 | 2025-09-25 | イノヴォ セラピューティクス、インコーポレイテッド | ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物 |
| JP2025540970A (ja) * | 2022-12-06 | 2025-12-17 | キャプター セラピューティクス エス．エー． | ユビキチンリガーゼ及びターゲットｍｃｌ－１タンパク質に結合する二機能性化合物を使用するターゲティングされたタンパク質分解 |
| WO2024123195A1 (en) * | 2022-12-06 | 2024-06-13 | Captor Therapeutics S.A. | Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
| CN120530094A (zh) * | 2023-01-12 | 2025-08-22 | 田边三菱制药株式会社 | Cereblon E3连接酶结合化合物、包含其的药物组合物及其制造方法 |
| WO2025045837A1 (en) | 2023-08-31 | 2025-03-06 | Syngenta Crop Protection Ag | Pesticidally active indazole compounds |
| CN117224547B (zh) * | 2023-09-12 | 2025-05-27 | 中国医科大学附属第一医院 | 一种小分子化合物dBET1在银屑病治疗中的应用 |
| AU2024344247A1 (en) | 2023-09-19 | 2026-05-07 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| WO2008007979A1 (en) * | 2006-07-12 | 2008-01-17 | Auckland Uniservices Limited | (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives |
| AU2007290407A1 (en) | 2006-08-30 | 2008-03-06 | Celgene Corporation | 5-substituted isoindoline compounds |
| HUE035389T2 (en) | 2006-09-26 | 2018-05-02 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
| EP2277869A1 (de) * | 2009-06-24 | 2011-01-26 | Bayer CropScience AG | Cycloalkylamidbenzoxa(thia)zole als Fungizide |
| SG183257A1 (en) | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| CN109153644B (zh) | 2016-03-16 | 2022-10-21 | H·李·莫菲特癌症中心研究有限公司 | 用以增强效应t细胞功能的针对cereblon的小分子 |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| JP7258009B2 (ja) | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| CN118108706A (zh) * | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| CA3095912A1 (en) | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CA3102212A1 (en) | 2018-06-29 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory compounds |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| MX2022004526A (es) * | 2019-10-17 | 2022-07-21 | Arvinas Operations Inc | Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6. |
-
2020
- 2020-11-27 JP JP2022532037A patent/JP7852923B2/ja active Active
- 2020-11-27 AU AU2020392427A patent/AU2020392427B2/en active Active
- 2020-11-27 KR KR1020227021713A patent/KR20220106801A/ko active Pending
- 2020-11-27 CN CN202080094725.5A patent/CN115023419A/zh active Pending
- 2020-11-27 WO PCT/EP2020/083596 patent/WO2021105334A1/en not_active Ceased
- 2020-11-27 EP EP20811632.7A patent/EP4065571A1/en active Pending
- 2020-11-27 US US17/780,891 patent/US20240343706A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008509166A5 (enExample) | ||
| JP2003531835A5 (enExample) | ||
| CA2533321A1 (en) | Bicyclic peptide imaging agents | |
| JP2020073472A5 (enExample) | ||
| JP2016153410A5 (enExample) | ||
| JP2023052201A5 (enExample) | ||
| JP2007530441A5 (enExample) | ||
| JP2020134860A5 (enExample) | ||
| JP2018524339A5 (enExample) | ||
| RU2218337C2 (ru) | Производные тиазола, способ их получения и фармацевтическая композиция на их основе | |
| JP2008510828A5 (enExample) | ||
| JP2020521740A5 (enExample) | ||
| JP2023535815A5 (enExample) | ||
| JP2005504042A5 (enExample) | ||
| JP2023544476A5 (enExample) | ||
| JP2008503484A5 (enExample) | ||
| JPWO2020004649A5 (enExample) | ||
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| TW200410960A (en) | Calcium receptor modulating agents | |
| JP2005526076A5 (enExample) | ||
| JP2005530811A5 (enExample) | ||
| JP2025507292A5 (enExample) | ||
| JP2006509842A5 (enExample) | ||
| JP2005508368A5 (enExample) | ||
| JP2023538524A5 (enExample) |